Progression Free Survival as endpoint in P2's
Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesothelioma—The EORTC Lung Cancer Group
Julie Francart, Catherine Legrand, Richard Sylvester, Martine Van Glabbeke, Jan P. van Meerbeeck, Annie Robert
From the European Organisation for Research and Treatment of Cancer; Université Catholique de Louvain, Brussels; and University Hospital, Ghent, Belgium
Address reprint requests to Julie Francart, MSc, Université Catholique de Louvain, Unité EPID 3034, Clos Chapelle-aux-champs, 30, BE-1200 Brussels, Belgium; e-mail: julie.francart@epid.ucl.ac.be
PURPOSE: Phase II cancer clinical trials play a key role in the development of new drugs. These trials should be designed to accurately determine if the drug should be abandoned or if it is sufficiently promising for further investigation in phase III trials. With new cytostatic agents or when the response assessment is difficult, using the progression-free survival rate (PFSR) at a fixed time point, such as 3, 4, 5, or 6 months, instead of the response rate (RR) as the primary end point is an alternative approach. To design future phase II trials, reference values for PFSRs that correspond to drugs with insufficient (P0) and sufficient (P1) clinical activity (CA) are necessary. This article provides these values in mesothelioma.
MATERIALS AND METHODS: The European Organisation for Research and Treatment of Cancer database registered ten closed mesothelioma trials (nine phase II trials and one phase III trial) with 523 total patients. Trials were grouped into three categories according to the published RR: significant (n = 259), moderate (n = 142), and insufficient (n = 122) CA.
RESULTS: The PFSRs at 3, 4, 5, and 6 months, respectively, were as follows: 72%, 67%, 51%, and 43% in the group with significant CA; 59%, 51%, 42%, and 35% with moderate CA; and 52%, 40%, 34%, and 28% with insufficient CA.
CONCLUSION: These values may be used to define relevant P0 and P1 values in future phase II mesothelioma trials that use PFSR as the primary end point.
Supported by a grant from the Fédération Belge contre le Cancer, Brussels, Belgium and by Grants No. 5U10 CA1488-34 and 5U10 CA11488-35 from the National Cancer Institute, Bethesda, MD.
Presented in part at the 5th International Meeting of French Society of Statistics (SFdS)–Statistical Innovations in Clinical Trials, Paris, France, September 26-27, 2005.
The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article. |
